Table 1.
Baseline characteristics of patient population
| Parameters | All patients, n = 102 | ICM, n = 54 (52.9%) | non‐ICM, n = 48 (47.1%) | P |
|---|---|---|---|---|
| Clinical characteristics | ||||
| Age (years) | 54 (20–84) | 50.5 (21–79) | 68.5 (20–84) | <0.001 |
| Male | 74 (72.5) | 40 (74.1) | 34 (70.8) | 0.825 |
| BMI (kg/m2) | 26.1 (19.9–52.0) | 26.5 (19.9–52) | 25 (19.9–31.2) | 0.603 |
| NYHA class ≥II | 88 (86.3) | 42 (77.8) | 46 (95.8) | 0.009 |
| Concomitant cardiac medication at study entry | ||||
| ß‐Blockers | 90 (88.2) | 47 (87.0) | 43 (89.6) | 0.765 |
| ACE‐I | 69 (67.6) | 34 (63.0) | 35 (72.9) | 0.299 |
| ARB | 23 (22.5) | 11 (20.4) | 12 (25.0) | 0.639 |
| Diuretics | 63 (61.8) | 26 (48.1) | 37 (77.1) | 0.004 |
| MRA | 54 (52.9) | 23 (42.6) | 31 (64.6) | 0.030 |
| Parameters of the left ventricle | ||||
| LVEF (%) | 40 (20–60) | 50 (25–60) | 35 (20–60) | 0.001 |
| LVEF <45% | 52 (51) | 20 (37) | 32 (66.7) | 0.003 |
| LVEDD (mm) | 51 (34–78) | 51 (34–78) | 52 (38–74) | 0.190 |
| LVEDD >55 mm | 40 (39.2) | 19 (35.2) | 21 (43.8) | 0.420 |
| Positive LGE | 46 (45.1%) | 26 (48.1) | 20 (41.7) | 0.687 |
| Biomarkers | ||||
| BNP (ng/L) | 384 (18–23 211) | 278 (24–23 211) | 544 (18–11 955) | 0.143 |
| TnI (μg/L) | 0.05 (0–5.6) | 0.07 (0–5.6) | 0.05 (0–0.34) | 0.184 |
| TnI >0.03 | 60 (69.0) | 33 (71.7) | 27 (65.9) | 0.645 |
| CRP (mg/dL) | 0.53 (0–24) | 0.62 (0–24) | 0.32 (0–4.6) | 0.080 |
| CRP >0.5 | 42 (41.2) | 26 (48.1) | 16 (33.3) | 0.160 |
| Virus‐positive endomyocardial biopsies | ||||
| Total | 26 (25.5) | 17 (31.5) | 9 (18.8) | 0.175 |
| EBV | 8 (7.8) | 5 (9.3) | 3 (6.3) | 0.719 |
| PVB19 | 10 (9.8) | 8 (14.8) | 2 (4.2) | 0.098 |
| HHV‐6 | 9 (8.8) | 5 (9.3) | 4 (8.3) | 1.000 |
| Influenza A/B | 2 (2.0) | 1 (1.9) | 1 (2.1) | 1.000 |
| CBV3 | 0 (0) | 0 (0) | 0 (0) | 1.000 |
| Myocardial fibrosis | ||||
| Mild | 29 (28.4%) | 21 (38.9) | 8 (16.7) | 0.024 |
| Moderate | 39 (38.2) | 20 (37.0) | 19 (39.6) | 0.675 |
| Severe | 24 (23.5) | 9 (16.7) | 15 (31.3) | 0.046 |
| Positive detection of immunohistological markers in the myocardium | ||||
| MHC II | 64 (62.7) | 50 (92.6) | 14 (29.2) | <0.001 |
| CD68 | 62 (60.8) | 50 (92.6) | 12 (25.0) | <0.001 |
| CD3 | 43 (42.2) | 41 (75.9) | 2 (4.2) | <0.001 |
ACE‐I, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BNP, B‐type natriuretic peptide; CBV, Coxsackie B virus; CRP, C‐reactive protein; EBV, Epstein–Barr virus; HHV‐6, human herpesvirus 6; ICM, inflammatory cardiomyopathy; LGE, late gadolinium enhancement; LVEDD, left ventricular end‐diastolic diameter; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; non‐ICM, non‐inflammatory cardiomyopathy; NYHA, New York Heart Association; PVB19, parvovirus B19; TnI, troponin I.
Values are n (%) or are given as median and interquartile range.
Significantly different values are presented in bold.